Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $161.00 by Analysts at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by investment analysts at Royal Bank of Canada from $165.00 to $161.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 50.13% from the stock’s previous close.

Several other research firms also recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They set a “hold” rating and a $136.00 price objective on the stock. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Evercore ISI decreased their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.82.

Sarepta Therapeutics Stock Up 0.4 %

Shares of NASDAQ:SRPT traded up $0.38 during midday trading on Thursday, hitting $107.24. 473,652 shares of the company’s stock traded hands, compared to its average volume of 813,602. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a twelve month low of $101.00 and a twelve month high of $173.25. The company has a market cap of $10.24 billion, a PE ratio of 85.79 and a beta of 0.75. The firm’s fifty day moving average price is $116.47 and its two-hundred day moving average price is $122.90.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of SRPT. Vanguard Group Inc. grew its stake in Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the period. Capital International Investors boosted its position in Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after buying an additional 285,100 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.